23例非小细胞肺癌患者肺癌组织和血浆中EGFR外显子21的基因突变检测

Detection of epidermal growth factor receptor exon 21 mutations in tissue and plasma in 23 cases of non-small cell lung cancer

目的证明可以从非小细胞肺癌患者血浆中检测到表皮生长因子受体(epidermal growth factorreceptor,EGFR)突变,且与肿瘤组织的突变情况相一致,建立一种从外周血液中快速、经济、准确检测EGFR外显子21基因突变的方法。方法同时取得23例非小细胞肺癌患者的肺癌组织和血浆,采用突变富集PCR方法检测外周血液中EGFR外显子21的基因突变,并将检测结果与肺癌组织的检测结果进行对比。结果 23例非小细胞肺癌患者的肺癌组织中共检测到8例EGFR外显子21突变,其中7例突变可以从患者的外周血液中检测到。结论可以从非小细胞肺癌患者外周血液中检测到EGFR突变,通过本方法,可以从外周血液中检测EGFR外显子21基因突变。

Objective To develop a novel method for detecting the exon 21 mutations of epidermal growth factor receptor（EGFR） from the non-small cell lung cancer patients＇ plasma.Methods The tissue samples and plasma of 32 non-small cell lung cancer patients were collected simultaneously,the results of detecting the exon 21 mutations of epidermal growth factor receptor（EGFR）from plasma compare with that from the tissue sample by the method of mutant-enriched PCR.Results Eight cases of the exon 21 mutation of epidermal growth factor receptor（EGFR） from 23 were detected from tissue samples,7 cases of the exon 21 mutation of epidermal growth factor receptor（EGFR） can be detected from plasma.Conclusions The EGFR mutation can be detected in plasma from patients with non-small lung cancer,the exon 21 mutations of EGFR can be detected by this method.